West Nile Virus

Clinics in Laboratory Medicine

Volumn 37, Issue 2, 2017, Pages 243-252

  Saxena, Vandana ^a   Bolling, Bethany G ^b   Wang, Tian ^c  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Flavivirus; Viral encephalitis; West Nile virus

Indexed keywords

CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; IMMUNE RESPONSE; MOSQUITO; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIREMIA; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE; WEST NILE VIRUS; WEST NILE VIRUS INFECTION; ANIMAL; BIRD; CULEX; DISEASE MODEL; EPIDEMIC; HAMSTER; HUMAN; LEPORIDAE; MOUSE; VIROLOGY; WEST NILE FEVER;

VIRUS VACCINE;

ANIMALS; BIRDS; CRICETINAE; CULEX; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; HUMANS; MICE; RABBITS; VIRAL VACCINES; WEST NILE FEVER; WEST NILE VIRUS;

EID: 85014296535     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2017.01.001     Document Type: Review

References (99)

1. 1 Nash, D., Mostashari, F., Fine, A., et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 344:24 (2001), 1807–1814.
2. 2 Anderson, J.F., Andreadis, T.G., Vossbrinck, C.R., et al. Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science 286:5448 (1999), 2331–2333.
3. 3 Lanciotti, R.S., Roehrig, J.T., Deubel, V., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286:5448 (1999), 2333–2337.
4. 4 Mostashari, F., Bunning, M.L., Kitsutani, P.T., et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 358:9278 (2001), 261–264.
5. 5 Gubler, D.J., The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis 45:8 (2007), 1039–1046.
6. 6 Kramer, L.D., Styer, L.M., Ebel, G.D., A global perspective on the epidemiology of West Nile virus. Annu Rev Entomol 53 (2008), 61–81.
7. 7 O'Leary, D.R., Marfin, A.A., Montgomery, S.P., et al. The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis 4:1 (2004), 61–70.
8. 8 Murray, K., Baraniuk, S., Resnick, M., et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect 134:6 (2006), 1325–1332.
9. 9 Vandenbelt, S., Shaikh, S., Capone, A. Jr., et al. Multifocal choroiditis associated with West Nile virus encephalitis. Retina 23:1 (2003), 97–99.
10. 10 Hershberger, V.S., Augsburger, J.J., Hutchins, R.K., et al. Chorioretinal lesions in nonfatal cases of West Nile virus infection. Ophthalmology 110:9 (2003), 1732–1736.
11. 11 Adelman, R.A., Membreno, J.H., Afshari, N.A., et al. West Nile virus chorioretinitis. Retina 23:1 (2003), 100–101.
12. 12 Gilad, R., Lampl, Y., Sadeh, M., et al. Optic neuritis complicating West Nile virus meningitis in a young adult. Infection 31:1 (2003), 55–56.
13. 13 Bains, H.S., Jampol, L.M., Caughron, M.C., et al. Vitritis and chorioretinitis in a patient with West Nile virus infection. Arch Ophthalmol 121:2 (2003), 205–207.
14. 14 Carson, P.J., Konewko, P., Wold, K.S., et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis 43:6 (2006), 723–730.
15. 15 Cook, R.L., Xu, X., Yablonsky, E.J., et al. Demographic and clinical factors associated with persistent symptoms after West Nile virus infection. Am J Trop Med Hyg 83:5 (2010), 1133–1136.
16. 16 Sadek, J.R., Pergam, S.A., Harrington, J.A., et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol 32:1 (2010), 81–87.
17. 17 Nolan, M.S., Podoll, A.S., Hause, A.M., et al. Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort. PLoS One, 7(7), 2012, e40374.
18. 18 Busch, M.P., Kleinman, S.H., Tobler, L.H., et al. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis 198:7 (2008), 984–993.
19. 19 Penn, R.G., Guarner, J., Sejvar, J.J., et al. Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin Infect Dis 42:5 (2006), 680–683.
20. 20 Murray, K., Walker, C., Herrington, E., et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis 201:1 (2010), 2–4.
21. 21 Petersen, L.R., Brault, A.C., Nasci, R.S., West Nile virus: review of the literature. JAMA 310:3 (2013), 308–315.
22. 22 Bolling, B.G., Moore, C.G., Anderson, S.L., et al. Entomological studies along the Colorado Front Range during a period of intense West Nile virus activity. J Am Mosq Control Assoc 23:1 (2007), 37–46.
23. 23 Goddard, L.B., Roth, A.E., Reisen, W.K., et al. Vector competence of California mosquitoes for West Nile virus. Emerg Infect Dis 8:12 (2002), 1385–1391.
24. 24 Andreadis, T.G., Anderson, J.F., Vossbrinck, C.R., et al. Epidemiology of West Nile virus in Connecticut: a five-year analysis of mosquito data 1999-2003. Vector Borne Zoonotic Dis 4:4 (2004), 360–378.
25. 25 Godsey, M.S. Jr., Blackmore, M.S., Panella, N.A., et al. West Nile virus epizootiology in the southeastern United States, 2001. Vector Borne Zoonotic Dis 5:1 (2005), 82–89.
26. 26 Godsey, M.S. Jr., King, R.J., Burkhalter, K., et al. Ecology of potential West Nile virus vectors in Southeastern Louisiana: enzootic transmission in the relative absence of Culex quinquefasciatus. Am J Trop Med Hyg 88:5 (2013), 986–996.
27. 27 Rutledge, C.R., Day, J.F., Lord, C.C., et al. West Nile virus infection rates in Culex nigripalpus (Diptera: Culicidae) do not reflect transmission rates in Florida. J Med Entomol 40:3 (2003), 253–258.
28. 28 Ciota, A.T., Kramer, L.D., Vector-virus interactions and transmission dynamics of West Nile virus. Viruses 5:12 (2013), 3021–3047.
29. 29 Stramer, S.L., Fang, C.T., Foster, G.A., et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 353:5 (2005), 451–459.
30. 30 Mezochow, A.K., Henry, R., Blumberg, E.A., et al. Transfusion transmitted infections in solid organ transplantation. Am J Transplant 15:2 (2015), 547–554.
31. 31 Kramer, L.D., Li, J., Shi, P.Y., West Nile virus. Lancet Neurol 6:2 (2007), 171–181.
32. 32 O'Leary, D.R., Kuhn, S., Kniss, K.L., et al. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics 117:3 (2006), e537–e545.
33. 33 Moore, C.G., Interdisciplinary research in the ecology of vector-borne diseases: opportunities and needs. J Vector Ecol 33:2 (2008), 218–224.
34. 34 Reisen, W.K., Landscape epidemiology of vector-borne diseases. Annu Rev Entomol 55 (2010), 461–483.
35. 35 Gould, E.A., Higgs, S., Impact of climate change and other factors on emerging arbovirus diseases. Trans R Soc Trop Med Hyg 103:2 (2009), 109–121.
36. 36 Reisen, W.K., Cayan, D., Tyree, M., et al. Impact of climate variation on mosquito abundance in California. J Vector Ecol 33:1 (2008), 89–98.
37. 37 Brault, A.C., Changing patterns of West Nile virus transmission: altered vector competence and host susceptibility. Vet Res, 40(2), 2009, 43.
38. 38 Kilpatrick, A.M., Meola, M.A., Moudy, R.M., et al. Temperature, viral genetics, and the transmission of West Nile virus by Culex pipiens mosquitoes. PLoS Pathog, 4(6), 2008, e1000092.
39. 39 Pogodina, V.V., Frolova, M.P., Malenko, G.V., et al. Study on West Nile virus persistence in monkeys. Arch Virol 75:1–2 (1983), 71–86.
40. 40 Tesh, R.B., Siirin, M., Guzman, H., et al. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis 192:2 (2005), 287–295.
41. 41 Suen, W.W., Uddin, M.J., Wang, W., et al. Experimental West Nile Virus infection in rabbits: an alternative model for studying induction of disease and virus control. Pathogens 4:3 (2015), 529–558.
42. 42 Appler, K.K., Brown, A.N., Stewart, B.S., et al. Persistence of West Nile virus in the central nervous system and periphery of mice. PLoS One, 5(5), 2010, e10649.
43. 43 Siddharthan, V., Wang, H., Motter, N.E., et al. Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation. J Virol 83:9 (2009), 4251–4261.
44. 44 Tesh, R.B., Xiao, S.Y., Persistence of West Nile virus infection in vertebrates. Diamond, M.S., (eds.) West Nile encephalitis virus infection viral pathogenesis and host response, 2009, Springer, New York, 361–377.
45. 45 Saxena, V., Xie, G., Li, B., et al. A hamster-derived West Nile virus isolate induces persistent renal infection in mice. PLoS Negl Trop Dis, 7(6), 2013, e2275.
46. 46 Wang, T., Town, T., Alexopoulou, L., et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10:12 (2004), 1366–1373.
47. 47 Errett, J.S., Suthar, M.S., McMillan, A., et al. The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol 87:21 (2013), 11416–11425.
48. 48 Town, T., Bai, F., Wang, T., et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 30:2 (2009), 242–253.
49. 49 Fredericksen, B.L., Keller, B.C., Fornek, J., et al. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 82:2 (2008), 609–616.
50. 50 Katze, M.G., He, Y., Gale, M. Jr., Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:9 (2002), 675–687.
51. 51 Samuel, M.A., Diamond, M.S., Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79:21 (2005), 13350–13361.
52. 52 Lazear, H.M., Pinto, A.K., Vogt, M.R., et al. Beta interferon controls West Nile virus infection and pathogenesis in mice. J Virol 85:14 (2011), 7186–7194.
53. 53 Thackray, L.B., Shrestha, B., Richner, J.M., et al. Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection. J Virol 88:19 (2014), 11007–11021.
54. 54 Daniels, B.P., Holman, D.W., Cruz-Orengo, L., et al. Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals. MBio 5:5 (2014), e01476–e01514.
55. 55 Lazear, H.M., Daniels, B.P., Pinto, A.K., et al. Interferon-lambda restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med, 7(284), 2015, 284ra259.
56. 56 Wang, T., Scully, E., Yin, Z., et al. IFN-gamma-producing gammadelta T cells help control murine West Nile virus infection. J Immunol 171:5 (2003), 2524–2531.
57. 57 Shrestha, B., Wang, T., Samuel, M.A., et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 80:11 (2006), 5338–5348.
58. 58 Welte, T., Lamb, J., Anderson, J.F., et al. Role of two distinct gammadelta T cell subsets during West Nile virus infection. FEMS Immunol Med Microbiol 53:2 (2008), 275–283.
59. 59 Fang, H., Welte, T., Zheng, X., et al. Gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection. FEMS Immunol Med Microbiol 59:1 (2010), 71–80.
60. 60 Diamond, M.S., Shrestha, B., Marri, A., et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77:4 (2003), 2578–2586.
61. 61 Diamond, M.S., Shrestha, B., Mehlhop, E., et al. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16:3 (2003), 259–278.
62. 62 Diamond, M.S., Sitati, E.M., Friend, L.D., et al. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 198:12 (2003), 1853–1862.
63. 63 Roehrig, J.T., Staudinger, L.A., Hunt, A.R., et al. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951 (2001), 286–297.
64. 64 Mehlhop, E., Diamond, M.S., Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203:5 (2006), 1371–1381.
65. 65 Mehlhop, E., Whitby, K., Oliphant, T., et al. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79:12 (2005), 7466–7477.
66. 66 Sitati, E.M., Diamond, M.S., CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 80:24 (2006), 12060–12069.
67. 67 Lanteri, M.C., O'Brien, K.M., Purtha, W.E., et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 119:11 (2009), 3266–3277.
68. 68 Graham, J.B., Da Costa, A., Lund, J.M., Regulatory T cells shape the resident memory T cell response to virus infection in the tissues. J Immunol 192:2 (2014), 683–690.
69. 69 Shrestha, B., Diamond, M.S., Role of CD8+ T cells in control of West Nile virus infection. J Virol 78:15 (2004), 8312–8321.
70. 70 Styer, L.M., Kent, K.A., Albright, R.G., et al. Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog 3:9 (2007), 1262–1270.
71. 71 Moser, L.A., Lim, P.Y., Styer, L.M., et al. Parameters of mosquito-enhanced West Nile Virus infection. J Virol 90:1 (2016), 292–299.
72. 72 Schneider, B.S., Soong, L., Girard, Y.A., et al. Potentiation of West Nile encephalitis by mosquito feeding. Viral Immunol 19:1 (2006), 74–82.
73. 73 Byrne, S.N., Halliday, G.M., Johnston, L.J., et al. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J Invest Dermatol 117:3 (2001), 702–709.
74. 74 Lim, P.Y., Behr, M.J., Chadwick, C.M., et al. Keratinocytes are cell targets of West Nile virus in vivo. J Virol 85:10 (2011), 5197–5201.
75. 75 Welte, T., Reagan, K., Fang, H., et al. Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J Gen Virol 90:Pt 11 (2009), 2660–2668.
76. 76 Bai, F., Kong, K.F., Dai, J., et al. A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J Infect Dis 202:12 (2010), 1804–1812.
77. 77 Ben-Nathan, D., Huitinga, I., Lustig, S., et al. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol 141:3–4 (1996), 459–469.
78. 78 Suthar, M.S., Diamond, M.S., Gale, M. Jr., West Nile virus infection and immunity. Nat Rev Microbiol 11:2 (2013), 115–128.
79. 79 Sejvar, J.J., Clinical manifestations and outcomes of West Nile virus infection. Viruses 6:2 (2014), 606–623.
80. 80 Beasley, D.W., Li, L., Suderman, M.T., et al. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296:1 (2002), 17–23.
81. 81 Beasley, D.W., Whiteman, M.C., Zhang, S., et al. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol 79:13 (2005), 8339–8347.
82. 82 Arjona, A., Foellmer, H.G., Town, T., et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 117:10 (2007), 3059–3066.
83. 83 Wang, P., Dai, J., Bai, F., et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J Virol 82:18 (2008), 8978–8985.
84. 84 Verma, S., Kumar, M., Gurjav, U., et al. Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology 397:1 (2010), 130–138.
85. 85 Samuel, M.A., Wang, H., Siddharthan, V., et al. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A 104:43 (2007), 17140–17145.
86. 86 Samuel, M.A., Diamond, M.S., Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 80:19 (2006), 9349–9360.
87. 87 Sampson, B.A., Armbrustmacher, V., West Nile encephalitis: the neuropathology of four fatalities. Ann N Y Acad Sci 951 (2001), 172–178.
88. 88 Shrestha, B., Gottlieb, D., Diamond, M.S., Infection and injury of neurons by West Nile encephalitis virus. J Virol 77:24 (2003), 13203–13213.
89. 89 Wang, Y., Lobigs, M., Lee, E., et al. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77:24 (2003), 13323–13334.
90. 90 Xiao, S.Y., Guzman, H., Zhang, H., et al. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 7:4 (2001), 714–721.
91. 91 Martin, D.A., Muth, D.A., Brown, T., et al. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38:5 (2000), 1823–1826.
92. 92 Dauphin, G., Zientara, S., West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 25:30 (2007), 5563–5576.
93. 93 Roehrig, J.T., West Nile virus in the United States - a historical perspective. Viruses 5:12 (2013), 3088–3108.
94. 94 De Filette, M., Ulbert, S., Diamond, M., et al. Recent progress in West Nile virus diagnosis and vaccination. Vet Res, 43, 2012, 16.
95. 95 Hayes, E.B., Komar, N., Nasci, R.S., et al. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 11:8 (2005), 1167–1173.
96. 96 Monath, T.P., Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci 951 (2001), 1–12.
97. 97 Ledizet, M., Kar, K., Foellmer, H.G., et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine 23:30 (2005), 3915–3924.
98. 98 Wang, T., Anderson, J.F., Magnarelli, L.A., et al. Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 167:9 (2001), 5273–5277.
99. 99 Qiao, M., Ashok, M., Bernard, K.A., et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis 190:12 (2004), 2104–2108.